

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from scanned originals with text recognition applied
(searchable text may contain some errors and/or omissions)



120th MAINE LEGISLATURE

FIRST REGULAR SESSION-2001

Legislative Document

No. 687

H.P. 532

House of Representatives, February 13, 2001

**An Act to Maintain a Centralized Database for Schedule II Prescriptions
Dispensed by Pharmacies in the State.**

Reference to the Committee on Business and Economic Development suggested and ordered printed.

Millicent M. MacFarland

MILLICENT M. MacFARLAND, Clerk

Presented by Representative BRUNO of Raymond.
Cosponsored by Representatives: MURPHY of Kennebunk, SCHNEIDER of Durham,
SHIELDS of Auburn, Senator: SHOREY of Washington.

2 **Be it enacted by the People of the State of Maine as follows:**

4 **Sec. 1. 32 MRSA §13724** is enacted to read:

6 **§13724. Database**

8 The board shall use information from quarterly reports
10 required in section 13796 to maintain a database containing all
12 transactions in the State involving schedule II drugs. For
14 purposes of this section, "schedule II drug" has the same meaning
16 as in the federal Controlled Substances Act of 1970, 21 United
18 States Code, Section 812.

20 **Sec. 2. 32 MRSA §13796** is enacted to read:

22 **§13796. Quarterly reports**

24 A facility registered under section 13751 shall provide to
26 the board on a quarterly basis a record of all transactions the
28 facility conducted in dispensing schedule II drugs, including the
30 name of the customer, type of drug and amount of drug for each
32 transaction. For purposes of this section, "schedule II drug"
has the same meaning as in the federal Controlled Substances Act
of 1970, 21 United States Code, Section 812.

SUMMARY

This bill requires pharmacies to provide the Maine Board of
Pharmacy with quarterly reports recording all schedule II drug
transactions so that the board can maintain a centralized
database.